Mostrando 10 resultados de: 11
Filtros aplicados
Publisher
Biomedicine and Pharmacotherapy(1)
Cell and Bioscience(1)
Current Pharmaceutical Design(1)
Expert Review of Neurotherapeutics(1)
Frontiers in Aging Neuroscience(1)
Área temáticas
Enfermedades(11)
Farmacología y terapéutica(5)
Fisiología humana(4)
Medicina y salud(4)
Problemas sociales y servicios a grupos(2)
Objetivos de Desarrollo Sostenible
ODS 3: Salud y bienestar(10)
ODS 10: Reducción de las desigualdades(9)
ODS 2: Hambre cero(4)
ODS 9: Industria, innovación e infraestructura(4)
ODS 12: Producción y consumo responsables(2)
Origen
scopus(11)
Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia
ArticleAbstract: Benzodiazepines (BZDs) and Z-drugs are compounds widely prescribed in medical practice due to theirPalabras claves:Alzheimer's disease, benzodiazepines, COGNITION, dementia, RISK FACTORSAutores:Antoni Camins, Auladell C., Bulló M., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusCurrent Research Therapeutic Strategies for Alzheimer's Disease Treatment
ReviewAbstract: Alzheimer's disease (AD) currently presents one of the biggest healthcare issues in the developed coPalabras claves:Autores:Abad S., Antoni Camins, Auladell C., Ettcheto M., Folch J., García M.L., Olloquequi J., Petrov D., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusDexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice
ArticleAbstract: Background: Several studies stablished a relationship between metabolic disturbances and Alzheimer´sPalabras claves:Alzheimer´s disease, APPswe/PS1dE9, Cognitive deficits, Dexibuprofen, High fat diet, Metabolic alterations, neuroinflammation, synapsis, unfolded protein response, βA plaquesAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Carrasco M., Espinosa-Jimenez T., Ettcheto M., Folch J., Herrera K., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusInhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease
ArticleAbstract: In this study, the effects of melatonin on MPP+-treated cerebellar granule neurons (CGNs) in culturePalabras claves:apoptosis, Calpain, caspase, CDK5, Cerebellar granule cells, MPP +Autores:Acuña-Castroviejo D., Alvira D., Antoni Camins, Folch J., Pallás M., Tajes M., Verdaguer E.Fuentes:scopusThe role of leptin in the sporadic form of Alzheimer's disease. Interactions with the adipokines amylin, ghrelin and the pituitary hormone prolactin
ReviewAbstract: Leptin (Lep) is emerging as a pivotal molecule involved in both the early events and the terminal phPalabras claves:Alzheimer's disease, amylin, Ghrelin, high-fat diet, hippocampus, insulin receptor, leptin, mTOR, obesity, PGC-1α, prolactinAutores:Abad S., Antoni Camins, Ettcheto M., Folch J., Martínez N., Miguel Marin, Patraca I., Pedros I., Petrov D., Zárate C.B.Fuentes:scopusReview of the advances in treatment for Alzheimer disease: Strategies for combating β-amyloid protein
OtherAbstract: Introduction Alzheimer disease (AD) is a major neurodegenerative disorder which eventually results iPalabras claves:Alzheimer disease, Amyloid hypotheses, Beta-amyloid, Beta-secretase, Gamma-secretaseAutores:Abad S., Antoni Camins, Ettcheto M., Folch J., Miguel Marin, Olloquequi J., Pedros I., Petrov D.Fuentes:scopusMasitinib for the treatment of alzheimer's disease
ArticleAbstract: The actual standard treatment for mild-to-moderately severe Alzheimer's disease only attacks its symPalabras claves:Alzheimer's disease, clinical trials, masitinib, mechanism of actionAutores:Antoni Camins, Auladell C., Cano A., Ettcheto M., Folch J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusMasitinib for the treatment of mild to moderate Alzheimer's disease
ReviewAbstract: Alzheimer's disease (AD) is a degenerative neurological disorder that is the most common cause of dePalabras claves:ALZHÉIMER, inflammation, masitinib, Neurodegeneration, TauAutores:Abad S., Antoni Camins, Auladell C., Ettcheto M., Folch J., Lazarowski A., Miguel Marin, Olloquequi J., Pedros I., Petrov D., Zárate C.B.Fuentes:scopusMemantine for the treatment of dementia: A review on its current and future applications
ReviewAbstract: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the presence in the brainPalabras claves:Alzheimer's disease, Amyloid-protein, Extrasynaptic N-Methyl-D-aspartate receptor, Memantine, Tau proteinAutores:Antoni Camins, Auladell C., Busquets O., Casadesús G., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Olloquequi J., Pelegrí Gabalda C., Sanchez-Lopez E., Verdaguer E., Vilaplana J., Zárate C.B.Fuentes:scopusMetabolic basis of sporadic Alzeimer’s disease. Role of hormones related to energy metabolism
ArticleAbstract: The more common sporadic form of Alzheimer disease (SAD) and the metabolic syndrome are two highly pPalabras claves:Adipokines, amylin, Ghrelin, leptin, prolactin, Sporadic Alzheimer diseaseAutores:Antoni Camins, Folch J., Martínez N., Patraca I., Pedros I., Sureda F.X.Fuentes:scopus